Penumbra (PEN) to Release Earnings on Tuesday

Penumbra (NYSE:PEN) is expected to be releasing its earnings data after the market closes on Tuesday, February 18th. Analysts expect Penumbra to post earnings of $0.88 per share and revenue of $311.63 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Penumbra Price Performance

PEN stock opened at $267.83 on Friday. The firm has a 50 day moving average of $255.04 and a 200-day moving average of $224.21. Penumbra has a 12-month low of $148.00 and a 12-month high of $277.89. The company has a current ratio of 5.82, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. The company has a market cap of $10.28 billion, a price-to-earnings ratio of 311.43, a PEG ratio of 1.92 and a beta of 0.53.

Insider Buying and Selling at Penumbra

In other news, CAO Lambert Shiu sold 1,798 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $242.56, for a total transaction of $436,122.88. Following the completion of the sale, the chief accounting officer now directly owns 20,682 shares in the company, valued at $5,016,625.92. This represents a 8.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Johanna Roberts sold 600 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $239.74, for a total value of $143,844.00. Following the sale, the executive vice president now owns 64,044 shares of the company’s stock, valued at approximately $15,353,908.56. The trade was a 0.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 33,819 shares of company stock worth $8,129,483. Insiders own 5.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PEN. Piper Sandler lifted their price target on shares of Penumbra from $235.00 to $250.00 and gave the company an “overweight” rating in a research report on Wednesday, November 20th. Wells Fargo & Company raised shares of Penumbra from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $190.00 to $275.00 in a research note on Wednesday, December 11th. UBS Group began coverage on shares of Penumbra in a research note on Tuesday, January 21st. They set a “buy” rating and a $305.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of Penumbra in a research note on Thursday, October 31st. Finally, Truist Financial raised their price objective on shares of Penumbra from $240.00 to $285.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $261.36.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.